Establishment Labs Holdings Inc.
ESTAHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeEstablishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa,. At a $1.90B market cap, Establishment Labs Holdings Inc. ranks as a small-cap company within healthcare. The company offers silicone gel-filled breast implants under the Motiva Implants brand.
Market Cap
$1.90B
Beta
1.06
P/E (TTM)
—
P/E (Fwd)
1063.33
EPS (TTM)
$-1.30
EPS (Fwd)
$0.06
ROE
-175.3%
ROA
-3.4%
Cash
$71.2M
Total Debt
$263.7M
Free CF
-$19.3M
52W Change
25.6%
Annual Financials
Cash vs Debt
Where ESTA stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, ESTA finished 21.19% below its 150-day moving average ($73.44) and 20.43% below its 200-day moving average ($72.74). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ESTA overbought or oversold?
At the October 15, 2026 close, ESTA's RSI(14) was 29.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $71.2M in cash, though total debt stands at $263.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$19.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -175.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $161.7M (2022) to $211.1M (2025), reflecting a 31% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Establishment Labs Holdings Inc.'s trajectory.